Open AccessCrizotinib‐associated renal cyst development may be associated with prolonged progression‐free survival in patients with ALK ‐positive non‐small‐cell lung cancer: Case report and review of the literature
Author(s) -
Wiest Nathaniel E.,
Tzou Katherine S.,
Olson Matthew T.,
Herchko Steven M.,
Bajalia Essa M.,
Thiel David D.,
Lou Yanyan,
Zhao Yujie,
Manochakian Rami
Publication year - 2021
Publication title -
clinical case reports
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.21
H-Index - 9
ISSN - 2050-0904
DOI - 10.1002/ccr3.4278
Subject(s) - crizotinib , medicine , anaplastic lymphoma kinase , lung cancer , tyrosine kinase inhibitor , tyrosine kinase , oncology , cancer , cancer research , pathology , receptor , malignant pleural effusion
Non‐small cell lung cancer patients with anaplastic lymphoma kinase or c‐ros oncogene 1 mutations who are treated with the tyrosine kinase inhibitor crizotinib rarely develop crizotinib‐associated renal cysts (CARCs). Here, we present a case report and review of the literature supporting the hypothesis that CARCs may correlate positively with progression‐free survival.